SS-LUP-332 vs SS LUP 332 — Same Peptide, Different Format

SS-LUP-332 vs SS LUP 332 — Same Peptide, Different Format

Those hyphens aren't marking a different peptide. Remove them and you have the exact same compound. SS-LUP-332 and SS LUP 332 are identical amino-acid sequences, just written two different ways. The confusion stems from inconsistent vendor naming conventions, not from differences in molecular structure, purity, or bioactivity. Both refer to the same research-grade peptide used in metabolic and cellular signalling studies, though the formatting variation appears across supplier catalogs, research publications, and laboratory ordering systems.

We've worked with hundreds of researchers navigating peptide procurement, and this naming discrepancy ranks among the most common ordering errors. The gap between recognizing a formatting difference and accidentally ordering duplicate stock comes down to knowing what makes peptide identifiers interchangeable versus distinct.

What's the difference between SS-LUP-332 and SS LUP 332?

SS-LUP-332 and SS LUP 332 are the same peptide compound. The hyphen is a typographic convention used by some suppliers and omitted by others. Both identifiers refer to an identical amino-acid sequence synthesized under the same purity standards (typically ≥98% by HPLC). The molecular weight, CAS number (if assigned), and biological activity remain constant regardless of which format appears on the supplier label.

The notation pattern. Uppercase letters, numeric suffix, optional hyphens. Follows standard research peptide nomenclature but lacks the regulatory standardization applied to FDA-approved drugs. Unlike semaglutide (which has a single INN designation), research peptides like SS-LUP-332 operate without universal naming enforcement. One catalog lists it hyphenated; another spaces it; a third might collapse it entirely into SSLUP332. All three point to the same compound.

This article covers what makes peptide identifiers equivalent despite formatting differences, how to verify you're ordering the correct compound when names vary, and what metadata actually matters when SS-LUP-332 appears under three different labels in three different databases.

Why Peptide Names Use Inconsistent Formatting

Research peptides don't follow the International Nonproprietary Name (INN) system that governs pharmaceutical drugs. When Novo Nordisk synthesizes semaglutide, that name is locked across every market. When a peptide synthesis facility produces SS-LUP-332, the identifier is internally assigned. Not globally standardized. Different labs adopt different conventions: some hyphenate prefix codes (SS-LUP-332), some use spaces (SS LUP 332), some run them together (SSLUP332).

The 'SS' prefix typically denotes a structural or sourcing category internal to the manufacturer. 'LUP' might reference a functional class, research lineage, or synthesis batch protocol. The '332' is a sequential identifier within that classification. None of these components are regulated nomenclature. A different supplier synthesizing the same sequence might label it entirely differently. Say, RP-LUP-332 or MetaSeq-332. While delivering chemically identical product.

Verification happens at the molecular level, not the label level. Certificate of Analysis (CoA) documents include HPLC chromatograms, mass spectrometry results, and amino-acid sequencing that confirm identity independent of naming. Two vials labeled SS-LUP-332 and SS LUP 332 from accredited 503B facilities will show identical spectrometric profiles because the underlying compound is identical. The hyphen exists in the catalog system, not in the peptide bond structure.

Our team has found that cross-referencing CAS numbers (when available), molecular weight, and sequence data eliminates ambiguity faster than trying to standardize name formats across vendors. If the CoA molecular weight matches within 0.1 Da and the HPLC purity exceeds 98%, the formatting of the product code is irrelevant.

How to Verify You're Ordering the Same Compound

Start with the molecular weight listed on the supplier's product page. SS-LUP-332 carries a specific molecular weight. Typically in the 1,200–1,800 Da range for short-chain peptides, though exact figures depend on sequence length. If two suppliers list different molecular weights for what they both call 'SS-LUP-332', you're looking at different compounds mislabeled under the same identifier.

Request the amino-acid sequence directly from the supplier before ordering. Reputable peptide vendors provide full sequence data (e.g., Ala-Gly-Ser-Leu-Tyr…) either on the product page or via technical support. Compare sequences character-by-character. If Vendor A lists a 12-residue sequence and Vendor B lists a 15-residue sequence, the hyphen difference is masking a more fundamental discrepancy. You're comparing two unrelated peptides that share a naming collision.

CAS Registry Numbers eliminate naming ambiguity entirely when assigned. Not all research peptides receive CAS numbers, but those that do gain a unique numerical identifier independent of supplier naming conventions. If SS-LUP-332 has an assigned CAS number, that number will appear identically across all legitimate sources. A supplier listing 'SS LUP 332' without the matching CAS number is either selling a different compound or operating outside standard chemical registry practices.

Mass spectrometry data from the Certificate of Analysis provides definitive confirmation. The molecular ion peak (M+H)+ should match the calculated mass for the stated sequence within ±0.5 Da for electrospray ionization (ESI) or ±1 Da for MALDI-TOF. If the experimental mass diverges beyond instrument error, the peptide inside the vial does not match the label. Regardless of whether that label reads SS-LUP-332, SS LUP 332, or anything else.

What Metadata Actually Determines Peptide Identity

Peptide identity rests on four non-negotiable parameters: amino-acid sequence, stereochemistry (L- vs D-form for each residue), post-translational modifications (acetylation, amidation, phosphorylation), and disulfide bond configuration. Everything else. Product codes, supplier names, batch numbers. Is metadata that points to these underlying structural features but does not define them.

Amino-acid sequence is the primary key. Two peptides with identical sequences but different product codes are the same compound. Two peptides with different sequences but similar product codes are unrelated compounds that happen to share a naming pattern. The sequence Ala-Gly-Ser-Leu-Tyr defines a specific peptide; calling it SS-LUP-332 or SS LUP 332 is a cataloging choice, not a molecular distinction.

Stereochemistry matters because L-amino acids and D-amino acids are non-superimposable mirror images with different biological activity. Standard peptide synthesis uses L-forms unless D-forms are explicitly specified. A peptide listed as 'SS-LUP-332 (all L-form)' is not equivalent to 'SS-LUP-332 (D-Ala substitution at position 3)' even though the product code looks identical. Sequence alone is insufficient. Chirality must match.

Post-translational modifications alter the molecular weight and bioactivity without changing the core amino-acid sequence. N-terminal acetylation adds 42 Da; C-terminal amidation adds 1 Da while removing 1 Da (net zero, but changes the charge state). A peptide synthesized with acetylation at the N-terminus is chemically distinct from the unmodified form. Suppliers should specify modifications in the product description, not just the name. If one vendor's SS-LUP-332 includes acetylation and another's does not, you're comparing modified vs unmodified peptides. Functionally different compounds despite identical names.

Disulfide bonds between cysteine residues lock peptides into specific three-dimensional conformations. Linear peptides (no cysteines or reduced cysteines) behave differently from cyclic or bridged forms. If SS-LUP-332 contains two cysteine residues, ask whether the supplier provides it in reduced (linear) or oxidized (bridged) form. The name won't tell you. The synthesis protocol will.

SS-LUP-332 vs SS LUP 332: Full Comparison

The table below compares the naming formats directly and shows what actually determines equivalence.

SS-LUP-332

Hyphenated prefix and suffix

Common in U.S. supplier catalogs and research publications

Identical to spaced format if sequence matches

Requires HPLC purity ≥98%, matching molecular weight, and sequence confirmation

Cross-check CAS number and sequence before assuming equivalence across vendors

SS LUP 332

Spaces separate components

Appears in European supplier systems and some database entries

Identical to hyphenated format if sequence matches

Same CoA parameters apply. Formatting does not alter chemical composition

Verify that 'SS LUP 332' references the same CAS number or provides sequence data matching hyphenated listings

SSLUP332 (collapsed)

No separators

Occasionally used in internal lab inventory systems

Identical if derived from the same synthesis protocol

Molecular weight and HPLC profile remain the definitive checks

Least common format. Primarily internal use, rarely appears on commercial labels

Key Takeaways

SS-LUP-332 and SS LUP 332 refer to the same peptide compound. The hyphen is a supplier formatting choice, not a molecular distinction.

Peptide identity is confirmed through amino-acid sequence, molecular weight (±0.1 Da), and HPLC purity (≥98%). Not through product code formatting.

CAS Registry Numbers, when assigned, eliminate naming ambiguity entirely by providing a unique numerical identifier independent of catalog conventions.

Certificate of Analysis documents (CoA) containing mass spectrometry and HPLC chromatograms are the only definitive proof that two differently labeled vials contain the same compound.

Stereochemistry (L- vs D-form) and post-translational modifications (acetylation, amidation) create functional differences even when amino-acid sequences are identical. Always verify modification status.

Ordering errors occur when researchers assume identical product codes across vendors without confirming sequence data. Cross-reference molecular weight and sequence before purchasing.

What If: SS-LUP-332 Scenarios

What If Two Suppliers List Different Molecular Weights for SS-LUP-332?

Order from neither until you resolve the discrepancy. Request the full amino-acid sequence from both suppliers and compare them residue-by-residue. If the sequences differ, one supplier is mislabeling a different peptide under the SS-LUP-332 identifier. This happens when internal catalog systems assign codes without cross-checking existing nomenclature. If the sequences match but molecular weights diverge by more than 1 Da, one supplier is reporting incorrect data or synthesizing impure product. Ask for recent CoA documentation showing HPLC purity above 98% and mass spectrometry confirming the calculated molecular weight. Only proceed with the supplier whose spectrometric data matches the expected mass for the stated sequence.

What If a Vendor Lists 'SS-LUP-332' Without Providing a CAS Number?

Not all research peptides receive CAS numbers, so the absence alone isn't disqualifying. However, if competing suppliers do list a CAS number for what they call SS-LUP-332, contact the vendor without the CAS and ask why theirs differs. It's possible they're selling a proprietary analog under a similar name, or that they haven't registered the compound formally. Request the amino-acid sequence, molecular weight, and a recent CoA. If those parameters match the CAS-registered version from other suppliers, the peptides are equivalent despite the missing registry entry. If the sequence differs or the vendor refuses to provide it, assume you're looking at a different compound and source elsewhere.

What If My Lab's Existing Stock Is Labeled 'SS LUP 332' but My New Order Arrives as 'SS-LUP-332'?

Compare the Certificates of Analysis for both batches. Check that the molecular weight matches within 0.1 Da, the HPLC purity exceeds 97%, and the amino-acid sequence is identical across both documents. If all three align, the formatting difference is cosmetic. The peptide inside both vials is the same. Store them together and treat them as a single compound in your inventory system. If the CoAs show divergent molecular weights or purity levels, treat them as separate entities regardless of name similarity. Use the higher-purity batch for critical assays and reserve the lower-purity stock for preliminary work or bulk applications where 95% purity suffices.

The Unvarnished Truth About Peptide Naming Conventions

Here's the honest answer: peptide naming in the research-grade market is a mess. Unlike pharmaceuticals, where semaglotide means semaglutide everywhere, research peptides operate in a regulatory gray zone where every supplier invents its own catalog codes. SS-LUP-332, SS LUP 332, and SSLUP332 might all point to the same compound. Or they might not. There's no enforcement mechanism ensuring consistency across vendors, and CAS number assignment lags years behind peptide synthesis timelines. You can't trust the name. You can only trust the Certificate of Analysis.

The format variation isn't malicious. It's a byproduct of decentralized synthesis operations where each facility builds its own inventory system without cross-referencing competitors. But the practical result is the same: researchers waste time and budget ordering what they think is a redundancy check (two vials from two vendors to confirm results) only to discover they've purchased two formulations of the same peptide or, worse, two completely different peptides mislabeled under similar codes.

If your peptide vendor won't provide sequence data, won't share recent CoA files, or lists molecular weights that don't align across their own product pages, find a different supplier. Real Peptides operates under the principle that identity verification precedes every shipment. Sequence data, molecular weight, and HPLC purity are published with every product listing because ambiguous peptides waste research hours and skew experimental results.

The bottom line: peptide equivalence is a molecular question, not a typographic one. Run the CoA comparison first, worry about catalog formatting never.

Every peptide synthesis starts with an amino-acid sequence. Not a product code. The code is shorthand invented after the fact to organize inventory systems that were never designed to interoperate. Two labs synthesizing the identical 12-residue sequence will produce chemically equivalent peptides even if one calls it SS-LUP-332 and the other labels it MetaChain-12A. The molecular structure dictates the biological activity; the name is just the label humans attach to simplify ordering.

When that label system breaks down. When hyphens appear and disappear, when spaces replace dashes, when suppliers adopt conflicting conventions. The only recourse is returning to first principles. Ignore the name. Pull the Certificate of Analysis. Compare the molecular weight to the calculated mass of the stated sequence. Verify that HPLC purity exceeds 98%. Confirm that the mass spectrometry peak matches the expected molecular ion. If those three checks pass, you're holding the same peptide regardless of what the bottle says.

Frequently Asked Questions

Yes, SS-LUP-332 and SS LUP 332 refer to the same peptide — the difference is purely typographic. The hyphenated format (SS-LUP-332) and spaced format (SS LUP 332) are naming conventions used by different suppliers to catalog identical amino-acid sequences. Molecular identity is confirmed through Certificate of Analysis documents showing matching molecular weight, HPLC purity above 98%, and identical mass spectrometry profiles. The peptide bond structure, bioactivity, and synthesis purity remain constant regardless of which format appears on the label.

Compare the Certificates of Analysis (CoA) for both vials and check three parameters: molecular weight (must match within ±0.1 Da), HPLC purity (both should exceed 97%), and amino-acid sequence (must be identical residue-by-residue). If a CAS Registry Number is assigned, confirm it matches across both suppliers. If molecular weights diverge by more than 1 Da or sequences differ, you’re comparing two unrelated peptides regardless of name similarity. Mass spectrometry data in the CoA provides definitive confirmation — the molecular ion peak should align with the calculated mass for the stated sequence.

Research peptides lack the International Nonproprietary Name (INN) standardization that governs pharmaceutical drugs. Each synthesis facility assigns internal product codes based on its own inventory system — some use hyphens, others use spaces, and some collapse identifiers entirely. The ‘SS’ prefix, ‘LUP’ designation, and ‘332’ suffix are internal classifications, not regulated nomenclature. Unlike semaglutide (which has a single global name), research-grade peptides operate without universal naming enforcement, so formatting inconsistencies appear across vendor catalogs even when the underlying molecular structure is identical.

Naming collisions occur when different suppliers assign similar codes to unrelated peptides or when one supplier mislabels a compound under an existing identifier used elsewhere. The practical risk is ordering what appears to be a redundancy check (two sources of SS-LUP-332 for result confirmation) but receiving two functionally different peptides. This skews experimental results and wastes research budget. Mitigation requires cross-referencing molecular weight, amino-acid sequence, and CAS numbers before purchase — never assume identical product codes guarantee identical compounds without verifying spectrometric data.

Yes, post-translational modifications like N-terminal acetylation or C-terminal amidation create chemically distinct peptides even when the core amino-acid sequence is identical. Acetylation adds 42 Da to the molecular weight and can alter bioactivity; amidation changes the charge state without significantly affecting mass. Two peptides labeled SS-LUP-332 — one acetylated, one unmodified — are functionally different compounds. Suppliers should specify modifications in product descriptions, and researchers must verify modification status through CoA documentation before assuming equivalence based on name alone.

Molecular weight is necessary but not sufficient for definitive identification. Two unrelated peptides can have similar molecular weights within 1–2 Da, especially for short sequences. Full confirmation requires molecular weight verification (±0.1 Da), amino-acid sequence comparison, HPLC purity analysis, and mass spectrometry showing the correct molecular ion peak. If a supplier provides only molecular weight without sequence data or CoA documentation, you cannot conclusively verify identity. Always request full spectrometric data before ordering, particularly when comparing peptides across vendors with inconsistent naming.

A Certificate of Analysis for research-grade peptides includes HPLC chromatogram showing purity percentage (typically ≥97%), mass spectrometry results confirming molecular weight and the presence of the correct molecular ion peak, amino-acid analysis or sequencing data, and appearance/solubility characteristics. The CoA is issued per synthesis batch and provides the only verifiable proof that the peptide inside the vial matches the stated identity on the label. Reputable suppliers provide CoAs upon request or publish them alongside product listings — suppliers who refuse CoA disclosure should be avoided.

Stereochemistry determines whether amino acids in the peptide are L-form (standard) or D-form (mirror-image). L-amino acids and D-amino acids are non-superimposable and exhibit different biological activity. A peptide synthesized with all L-form residues is not equivalent to one containing D-form substitutions at specific positions, even if the amino-acid sequence otherwise matches. Suppliers should specify stereochemistry in product descriptions. If Vendor A lists ‘SS-LUP-332 (all L-form)’ and Vendor B lists ‘SS-LUP-332 (D-Ala at position 3)’, you’re comparing functionally distinct compounds despite identical product codes.

HPLC purity reflects the percentage of the target peptide relative to synthesis by-products, truncation sequences, and deletion peptides in the final product. Different synthesis protocols, purification methods (preparative HPLC vs flash chromatography), and quality control thresholds result in batch-to-batch purity variation. One supplier might release batches at 95% purity while another requires ≥98%. Both are selling chemically equivalent peptides, but the higher-purity batch contains fewer impurities. For critical assays requiring precise dosing, higher purity (≥98%) is preferred; for bulk applications or preliminary screening, 95% purity suffices.

Contact the supplier immediately and request the Certificate of Analysis for the batch that shipped. Compare the CoA molecular weight, amino-acid sequence, and HPLC purity to the specifications listed for the product you intended to order. If all three match, the shipment is correct and the code discrepancy is a catalog error or rebranding. If the molecular weight differs by more than 1 Da or the sequence does not match, you received the wrong compound — request a replacement or refund. Do not use peptides with unverified identity in experiments, as misidentified compounds invalidate results.

Yes, if the peptide contains cysteine residues capable of forming disulfide bridges. Suppliers may provide the peptide in reduced (linear) form with free thiols or oxidized (bridged) form with disulfide bonds linking specific cysteines. The oxidized form is typically more stable and biologically active, but some applications require the reduced form for controlled folding studies. If the product description does not specify disulfide configuration, contact the supplier before ordering. Two batches labeled SS-LUP-332 — one reduced, one oxidized — are structurally different despite identical amino-acid sequences.

No regulatory body enforces naming standardization for research-grade peptides. Unlike FDA-approved drugs, which receive International Nonproprietary Names (INN) governed by the WHO, research peptides are assigned internal catalog codes by individual suppliers without cross-vendor coordination. The CAS Registry (managed by the American Chemical Society) provides unique numerical identifiers for registered compounds, but not all peptides receive CAS numbers, and assignment lags years behind synthesis timelines. Researchers must rely on molecular verification (sequence, molecular weight, CoA data) rather than product names when confirming peptide identity across suppliers.